Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to a reduction in lesion size and allowed some patients to avoid surgery, according to research from a Phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22.
Source link
Intralesional nivolumab may be effective against precancerous oral lesions, Phase I trial results indicate
April 21, 2026
0 Comments
Explore More
Giant DNA discovered in people’s mouths could impact oral health, immunity and even cancer risk
A schematic describing what Inocles do and where they’re found. It shows the kinds of roles its genes might have, and how those jobs could be connected to things happening
Maternal periodontal disease linked to infant gut inflammation and long-term disease risk
Mice born from dams with artificially induced periodontitis (MatOP) are prone to developing inflammatory bowel disease. Credit: Cell Reports (2025). DOI: 10.1016/j.celrep.2025.115974 A new study demonstrates that maternal oral dysbiosis
New therapy eliminates gum disease bacterium while preserving beneficial oral microbes
Researchers at Nagoya University in Japan have created an innovative treatment for periodontitis that targets and eliminates harmful bacteria while preserving beneficial oral microbes essential for health. The findings were